Replies to post #133484 on Biotech Values

[stockbettor]

FWIW, NKTR's 118 slide at last year's JP Morgan presentation showed that AZN projects the market for OIC drugs at $6B, so there should be more than enough potential revenue for different types of OIC drugs to share:

• Oral drug with high relative bioavailability
• Peripheral opioid receptor antagonist
targets underlying cause of OIC and
preserves analgesia
• OIC market represents ~$6 billion in
annual global sales*
• Partnered with AZ for significant
milestones and significant double-digit
royalties
• AZ targeting start of Phase 3 - Q1 2011

*Source: 2010 MAT AstraZeneca